Combination of low doses of ONX 0912 and bortezomib, MS-275, Dex, or lenalidomide enhances MM cell death. (A) Low doses of ONX 0912 and bortezomib trigger synergistic anti-MM activity in MM cells. MM.1S cells were treated for 24 hours with indicated concentrations of ONX 0912, bortezomib, or ONX 0912 plus bortezomib and then assessed for viability using MTT assays. Isobologram analysis shows the synergistic cytotoxic effect of ONX 0912 and bortezomib in MM.1S cell line. The graph (left) is derived from the values given in the table (right). The numbers 1-4 in the graph represent combinations shown in the table. CI < 1 indicates synergy. Numbers represent FA (Fraction Affected) values (eg, FA = 0.5 corresponds to 50% decrease in viability or IC₅₀ for agent). All experiments were performed in triplicate and mean value is shown. FA_Com = fraction of cells showing decrease in viability with ONX 0912 plus bortezomib treatment. (B) Low doses of ONX 0912 and MS-275 trigger synergistic anti-MM activity in MM cells. MM.1S cells were treated for 48 hours with indicated concentrations of ONX 0912, MS-275, or ONX 0912 plus MS-275 and then assessed for viability using MTT assays. Isobologram analysis shows the synergistic cytotoxic effect of ONX 0912 and MS-275 in MM.1S cell line. The graph (left) is derived from the values given in the table (right). The numbers 1-6 in the graph represent combinations shown in the table. CI < 1 indicates synergy. (C) MM.1S cells were treated for 48 hours with indicated concentrations of ONX 0912, Dex, or ONX 0912 plus Dex and then assessed for viability using MTT assays. Shown is mean ± SD of 3 independent experiments. (D) MM.1S cells were treated for 48 hours with indicated concentrations of ONX 0912, lenalidomide, or ONX 0912 plus lenalidomide and then assessed for viability using MTT assays. Shown is mean ± SD of 3 independent experiments.